NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site
Portfolio Pulse from
NKGen Biotech has appointed Dr. Anita Fletcher as the National Principal Investigator for its Phase 2a trial of troculeucel, an NK cell therapy for moderate Alzheimer's disease. AdventHealth Orlando will be the first East Coast site for patient enrollment.
February 19, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NKGen Biotech has appointed Dr. Anita Fletcher as National PI for its Phase 2a trial of troculeucel for Alzheimer's. AdventHealth Orlando is the first East Coast site, potentially accelerating patient enrollment and trial progress.
The appointment of a National PI and the addition of a new trial site on the East Coast could accelerate the trial's progress, potentially leading to positive developments for NKGen's Alzheimer's treatment. This is likely to be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100